ALMS

US$27.26

Price alerts

Get one email when ALMS crosses your level. Checked every 15 minutes during market hours.

▼ -1.55 (-5.38%)down today

Open: US$28.70
High: US$28.77
Low: US$27.18
Prev close: US$28.81

USD · data via Finnhub · delayed/cached up to 1–5 min

Technicals

RSI (14-day)

54.5

Neutral

Above 70 can signal overbought; below 30, oversold.

MACD

1.40

Bearish momentum

MACD below its signal line (1.48).

50-day average

24.00

Price above

Short-term trend reference.

200-day average

18.66

Price above

Long-term trend reference.

Daily values · indicators are descriptive, not trading advice

About Alumis Inc.

Healthcare · Biotechnology

Alumis Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for immune-mediated diseases, aiming to replace broad immunosuppression with precision medicines. The company leverages its proprietary precision data analytics platform, biological insights, and expertise in immunology to advance a late-stage portfolio of next-generation treatments. Key pipeline assets include ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor targetin…

www.alumis.com

Key metrics

Market cap: $3.5B
P/B: 4.94
52-week high: 31.35
52-week low: 3.25
Return on equity: -54.7%
Net margin: -1013.2%
Beta: 0.77
1-year return: 657.8%
YTD return: 179.5%

Analyst recommendations

8 strong buy · 7 buy · 2 hold · 0 sell · 0 strong sell (17 analysts, 2026-07-01)
8 strong buy · 7 buy · 2 hold · 0 sell · 0 strong sell (17 analysts, 2026-06-01)
8 strong buy · 8 buy · 1 hold · 0 sell · 0 strong sell (17 analysts, 2026-05-01)
8 strong buy · 8 buy · 1 hold · 0 sell · 0 strong sell (17 analysts, 2026-04-01)

Similar stocks

Companies in the same industry, via Finnhub

AI research for ALMS

Get an AI-written, balanced deep-dive — performance, valuation, technicals, and the bull vs. bear case. Sign in to get started.

Analyze ALMS with AI →